DrugDashboards

Teglutik

Riluzole · RILUZOLE 5 mg/mL · Liquid · Oral · Edw Pharma

NDC 70726-0305-01 · 300 mL in 1 BOTTLE, PLASTIC · UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “requirements related to complying with good manufacturing practices.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 70726-0304-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$6.71per unit
middle half $6.65$6.75 · 249 plans · Jan 1, 2025
Est. net of rebates
≈ $6.71
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 4 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $4,131.44 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

  • In shortage now Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)Jan 26, 2024
    month 32 — 3× the typical 12-month other shortage · model puts 53% odds it resolves within 6 months
  • In shortage now Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)Jan 26, 2024
    month 32 — 3× the typical 12-month other shortage · model puts 53% odds it resolves within 6 months
  • In shortage now Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)Jan 26, 2024
    month 32 — 3× the typical 12-month other shortage · model puts 53% odds it resolves within 6 months
  • In shortage now Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)Jan 26, 2024
    Requirements related to complying with good manufacturing practices
    month 32 — 3× the typical 12-month other shortage · model puts 53% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Riluzole (Liquid)

LabelerStrengthFirst seenLast seen
Edw Pharma, IncRILUZOLE 5 mg/mLJul 15, 2026Sep 2, 2026
Edw Pharma, IncRILUZOLE 50 mg/10mLJul 15, 2026Sep 2, 2026
Edw PharmaRILUZOLE 5 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Teglutik — NDC 70726-0305-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70726030501.

Free to cite with attribution — see how the data is put together.